Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck Serono experiences first quarter growth

Merck Serono experiences first quarter growth

28th April 2010

Merck Serono has seen its revenues increase year-on-year in the first quarter of 2010, driven by strong sales of its leading pharmaceutical products.

According to the Merck KGaA group’s latest financial report, Merck Serono’s total revenue for the three month period came to 1.4 billion euros (1.2 billion pounds), up from 1.3 billion euros in the corresponding period of 2009.

Improved global sales of key biological therapies Rebif and Erbitux were cited as key drivers behind this increase, with the two treatments seeing year-on-year sales growth of 17 per cent and 19 per cent respectively.

Other Merck Serono drugs to see improved sales in the quarter include the growth hormone Saizen and the Gonal-f range of fertility products.

Based on these results, the Merck KGaA group now expects Merck Serono to see an increase in total revenues of between two and five per cent for the full year.

Earlier this month, Merck Serono reported results from a new clinical trial of its tablet-based cladribine treatment for multiple sclerosis, with the findings supporting the drug’s efficacy.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.